CONMED (CNMD)

• Market cap: $1.83B
• 1 day: -1.64%
• 5 days: -1.64%
• 1 month: 1.83%
• 3 months: -11.80%
• 6 months: -13.01%
• Year to date: -11.80%
• 1 year: -24.78%
• 5 years: 18.07%
• 10 years: 16.06%
• Sector: Healthcare
• Industry: Electromedical & Electrotherapeutic Apparatus

About: Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.

Employees: 4,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

731% more call options, than puts

Call options by funds: $8.3M | Put options by funds: $999K

4.88% more ownership

Funds ownership: 111.15% [Q3] → 116.03% (+4.88%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

1% less capital invested

Capital invested by funds: $2.46B [Q3] → $2.45B (-$12.7M) [Q4]

2% less repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 98

7% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 42

3% less funds holding

Funds holding: 286 [Q3] → 276 (-10) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $70 18% upside
• Avg. target: $77 29% upside
• High target: $91 53% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

Stifel Rick Wise 43% 1-year accuracy 15 / 35 met price target	26% upside $75	Buy Maintained	6 Feb 2025
Wells Fargo Vik Chopra 36% 1-year accuracy 4 / 11 met price target	18% upside $70	Equal-Weight Maintained	6 Feb 2025
Needham Mike Matson 40% 1-year accuracy 50 / 124 met price target	53% upside $91	Buy Maintained	6 Feb 2025
JP Morgan Robbie Marcus 53% 1-year accuracy 10 / 19 met price target	18% upside $70	Neutral Downgraded	6 Feb 2025